Nature Based Therapy With Mindful Walks in Urban Coastal Setting - Barcelona (Spain)
NATURE-MET-B
NATURE-based Therapy in Urban Coast in Barcelona (NATURE-MET-B)
2 other identifiers
interventional
100
1 country
1
Brief Summary
The main objective of the NATURE-MET-B (Barcelona) study is to analyze the effects of a Nature-based Therapy (NbT) on the biopsychological resilience of adults general population through changes in: i) health-related quality of life and ii) allostatic load (physiological stress). The secondary objective is to provide data on the environmental, social, and economic aspects of the intervention in order to refine specific prevention programs and establish programs that include NbT as a secondary preventive measure in healthcare. Analogous to NATURE-MET-B, two similar NbT studies will be carried out in Padua (Italy) and Salzburg (Austria) for the secondary prevention of Metabolic Syndrom (MetS). These are not multicenter studies but three comparable studies with similar inclusion and exclusion criteria in all study locations. Only the types of landscape and natural exposure sites differ: Barcelona-Coastal Urban, Padua-Urban Green, Salzburg-Mountainous Rural.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Sep 2024
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 2, 2024
CompletedFirst Submitted
Initial submission to the registry
September 30, 2024
CompletedFirst Posted
Study publicly available on registry
October 2, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 30, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
October 22, 2025
CompletedDecember 5, 2025
November 1, 2025
11 months
September 30, 2024
November 27, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
Health-related quality of life (SF-12)
The SF-12 (Short Form 12) is a widely used survey instrument that measures health-related quality of life (HRQoL). It is a shorter version of the SF-36, designed to assess a person´s physical and mental health status through 12 questions. The SF-12 provides a quick and reliable means to evaluate the impact of health on an individual's quality of life, making it useful in clinical settings and research.
From enrollment to the end of treatment of treatment (5 weeks) and follow up (10 weeks)
Allostatic Index-ALI
The Allostatic Index (ALI) is a biomarker-based measure designed to assess the cumulative physiological burden of stress on the body over time. It reflects the wear and tear on the body caused by chronic stress and the body\'s response to it, offering insights into an individual\'s health status and risk for various diseases.
From enrollment to the end of treatment of treatment (5 weeks) and follow up (10 weeks)
Scale of Positive and Negative Experience (SPANE)
The Scale of Positive and Negative Experience (SPANE) is a brief, self-report measure designed to assess an individual\'s emotional experiences over a specified period. SPANE provides insights into both positive and negative feelings, contributing to the broader understanding of subjective well-being and emotional health.
From enrollment to the end of treatment of treatment (5 weeks) and follow up (10 weeks)
Secondary Outcomes (20)
Environmental Concerns
From enrollment to the end of treatment of treatment (5 weeks) and follow up (10 weeks)
Revised Pro-Environmental Behavior Scale (R-PEBS)
From enrollment to the end of treatment of treatment (5 weeks) and follow up (10 weeks)
Quality-Adjusted Life Years (QUALYs)
From enrollment to the end of treatment of treatment (5 weeks) and follow up (10 weeks)
Healthcare and Social System Utilization (Cost Savings)
From enrollment to the end of treatment of treatment (5 weeks) and follow up (10 weeks)
Willingness to Pay (WTP)
From enrollment to the end of treatment of treatment (5 weeks) and follow up (10 weeks)
- +15 more secondary outcomes
Study Arms (2)
Intervention Grop
EXPERIMENTAL* Adults aged \>=18 years * Smartphone users * Understand Spanish and/or Catalan language
Control group
ACTIVE COMPARATOR* Adults aged \>=18 years * Smartphone users * Understand Spanish and/or Catalan language The control group participants are assessed at the same time as those in the intervention group (t1, t2, and t3). Participants in the control group will be offered the opportunity to benefit from the NbT once the follow-up period is completed (day 70).
Interventions
The intervention consists of a 5-week (35-day) conscious immersion treatment in a natural coastal urban environment, involving approximately three sessions per week of semi-structured walking and mindfulness exercises lasting 60 minutes. Following this, there will be a follow-up period that will end 5 weeks after the intervention has concluded (day 70). Participants will document and evaluate the therapy sessions at the location where the mindfulness exercises take place, using the mobile phone application App, a digital tool for assessing the environment and health. The aim is to integrate nature-based physical activity and relaxation sessions into daily life. The intervention will be standardized as much as possible to allow comparison of the results with those from the other study centers in Salzburg (Vienna) and Padua (Italy).
Participants in the control group will be offered the opportunity to benefit from the NbT once the follow-up period is completed (day 70).
Eligibility Criteria
You may qualify if:
- Adults \>=18 years
- Smartphone users
You may not qualify if:
- Acute contraindications
- \- Malignant hypertension
- Contraindications or differential diagnosis
- Severe respiratory or pulmonary disease (COPD, severe asthma, emphysema)
- Arteriosclerotic incident (e.g., myocardial infarction) 6 months previous the study starting
- Heart failure
- Uncontrolled metabolic diseases (e.g., diabetes mellitus)
- Diagnosis or treatment of a malignant disease \< 3 years ago
- Chronic immunological diseases (e.g., rheumatoid arthritis)
- Orthopedic conditions that prevent participation in excursions
- Factors that prevent or hinder participation in the intervention program
- Alcohol or substance abuse (except nicotine)
- Pregnancy
- Insufficient knowledge of Spanish or Catalan (written and spoken/questionnaires)
- Factors that prevent self-management
- +6 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
ISGlobal
Barcelona, Barcelona, 08003, Spain
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 30, 2024
First Posted
October 2, 2024
Study Start
September 2, 2024
Primary Completion
July 30, 2025
Study Completion
October 22, 2025
Last Updated
December 5, 2025
Record last verified: 2025-11
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL
Adequate measures will be implemented to ensure the protection and confidentiality of personal data, in accordance with Regulation (EU) 2016/679 on the Protection of Individuals with Regard to the Processing of Personal Data and on the Free Movement of Such Data, and Organic Law 3/2018, of December 5, on Personal Data Protection and the Guarantee of Digital Rights. National regulations on personal data protection will be implemented to ensure the highest standards in personal data management. Legality, fairness, and transparency; purpose limitation of processing; data minimization (only the necessary and relevant data for the research purpose will be collected); accuracy; storage limitation; and integrity and confidentiality will be applied when processing personal data. Personal data will not be transferred, except in cases permitted by law. Results will refer to analyses of aggregated data, no individual names will be associated with any published or unpublished report.